Gaurav Kaushik, Managing Director and CEO,
METEORIC BIOPHARMACEUTICALS
"We are looking into new ways to reap the benefits of artificial intelligence, particularly on the clinical side. On the physical side, Meteoric Biopharmaceuticals will have a new factory and lab up and running by the end of 2024, that will work on advanced fermentation processes."
What are the core business lines of Meteoric Biopharmaceuticals?
Meteoric Biopharmaceuticals was founded in 2006 with a focus on biological enzymes used for animal healthcare. The company quickly expanded its portfolio for other industries and is currently working on the probiotics side. With probiotics, we work on natural isolates of bacteria to study their health benefits before running clinical trials and launching products to companies targeting a particular need-based therapy. Meteoric Biopharmaceuticals is also focusing on expanding its portfolio of synthetic alternatives to animal-derived biologicals. Alongside strong support from the government and other stakeholders, we invest much of our earnings back into our R&D efforts.
Can you provide an example of an innovative enzyme your company has brought to the market?
The enzyme portfolio for any company is dominated by animal-derived enzymes like pepsin and pancreatin that often come from pigs or cows. As the world is moving towards veganism, Meteoric Biopharmaceuticals developed a vegan alternative to pancreatin. This has been very popular in countries that do not consume pork for religious reasons. Additionally, the science supports our product because it is completely virus and antibiotic free. When extracting a product from an animal, there is always room for variation based on which part of the world the animal lives in and what health conditions it has. Our products overcome these challenges.